PROCEADE-CRC-01: an anti-CEACAM5 ADC for metastatic colorectal cancer

Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents findings from the Phase I PROCEADE-CRC-01 trial (NCT05464030) of M9140, an anti-CEACAM5 antibody-drug conjugate (ADC), in metastatic colorectal cancer. Designed with an exatecan payload, this ADC showed promising results due to its stability and specific targeting of CEACAM5-expressing tumors. In the dose escalation study, administered intravenously every few weeks, dose-limiting toxicities were primarily hematological with no interstitial lung disease or ocular toxicity and only mild diarrhea and vomiting. Favorable pharmacokinetics demonstrated dose proportionality and low free exatecan levels in the bloodstream, with encouraging duration of treatment and progression-free survival (PFS) rates. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.